lifevantage reviews glp 1 How a supplement company became a haven for misinformation Protandim® Nrf2 Synergizer®* | LifeVantage

11.6 Evidence-Based Position Based on current literature: GLP-1 receptor agonists do not inherently cause universal nutrient depletion Intake-related vulnerability is plausible and patient-dependent Long-term micronutrient data remain limited Risk increases with magnitude and duration of weight loss Structured dietary strategy is protective Weight loss pharmacotherapy should be paired with nutritional planning

doi: 10.1159/000330447 74 HegedsLShermanSITuttleRMvon ScholtenBJRasmussenSKarsblJDet al

New York, with its finance and media dominance, came in third

Still, its a good potential customer acquisition strategy for Novo Nordisk, Leventhal said, because its tapping into a retailer that has a very, very loyal and large customer base. Overall, GLP-1s are getting cheaper, he added, because companies like Novo Nordisk and Eli Lilly, which makes GLP-1s Zepbound and Mounjaro, want to compete with the compounding market

Even more impressively, during the SURMOUNT-1 trial, study volunteers who used the highest dose (15mg) of tirzepatide lost as much as 21% of their body weight-equivalent to an average of 52 pounds